NCT07697716Not yet recruiting
In Vitro NSCLC EGFR-Mutant Models for Drug Sensitivity Testing
Targeting EGFR in Lung Cancer: Role of EGFR Mutation State and Bypass Routes in Drug Response and Resistance
Source: ClinicalTrials.gov · Last updated 13 Jul 2026
Brief summary (registry, in English)
The PRECISE-EGFR study is a prospective, observational project designed to generate patient-derived in vitro models (cell cultures and organoids) from individuals with non-small cell lung cancer (NSCLC) carrying EGFR mutations. These models will be used to evaluate sensitivity to different anti-EGFR therapies and explore mechanisms of drug resistance. Using residual biological samples collected during routine clinical practice, the study will not interfere with patient care. Researchers will also compare the molecular characteristics of the models with the original tumors to ensure reliability. The overall aim is to improve precision oncology approaches, identifying the most effective treatments for specific EGFR mutation subtypes while minimizing toxicity and resistance.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 30 (estimated)
- First submitted
- 7 Jul 2026
- Start date
- 1 Sept 2026
- Primary completion date
- 1 Sept 2026
- Lead sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Diseases
- Lung cancer
- NCT number
- NCT07697716
What you commit to
- Study type: Observational
- Planned participants: 30
- From 1 Sept 2026 to the primary completion date, 1 Sept 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients who have not provided written informed consent will be excluded from the study.
Who the study is looking for
- Age ≥ 18 years.
- Diagnosis of non-small cell lung cancer (NSCLC), regardless of the line of treatment.
- Documented presence of an EGFR mutation.
- Availability of residual biological material obtained from diagnostic or therapeutic procedures performed as part of routine clinical practice.
- Signed written informed consent for study participation.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.